Abeona Therapeutics
ABEO
70 hedge funds and large institutions have $43.4M invested in Abeona Therapeutics in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 24 reducing their positions, and 23 closing their positions.
2% more call options, than puts
Call options by funds: $209K | Put options by funds: $204K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.15% less ownership
Funds ownership: 1.26% → 1.11% (-0.15%)
7% less funds holding
Funds holding: 75 → 70 (-5)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
25% less capital invested
Capital invested by funds: $58.2M → $43.4M (-$14.8M)
50% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.24M |
| 2 |
Morgan Stanley
New York
|
+$2.1M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$1.17M |
| 4 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
+$816K |
| 5 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$490K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.44M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.85M |
| 4 |
Renaissance Technologies
New York
|
-$982K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$799K |
ABEO Hedge Fund Activity: Q2 2021 in Review
70 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q2 2021, worth a combined $43.4M — down 25% from $58.2M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ABEO and 18 opened new positions — a net loss of 5 holders — while 24 trimmed existing stakes and 12 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.24M. The largest seller was BlackRock, cutting an estimated $5.44M.
- 70 institutional investors held Abeona Therapeutics (ABEO) as of Q2 2021, down from 75 in Q1 2021.
- Funds reported $43.4M of Abeona Therapeutics stock for Q2 2021, down 25% quarter-over-quarter.
- 18 funds opened new Abeona Therapeutics positions in Q2 2021 and 23 closed out, a net change of -5 holders.
- The largest Abeona Therapeutics buyer in Q2 2021 was Millennium Management, an estimated $2.24M added.
- The largest Abeona Therapeutics seller in Q2 2021 was BlackRock, an estimated $5.44M sold.
Based on aggregated 13F filings for Q2 2021.